"There are many questions that should be answered when company tries to shift the focus of investors to other markets in order to mask the failure keeping lockdown as excuse where as healthcare across the world is blooming specially technology enabled solutions at home."
The other issue is that if the operating expenses were ($7.3m) which included, among other things, manufacturing and marketing for a commercial launch in Australia (their home market), imagine what these expenses will look like if/when they try to launch in the UK/US?
The cash balance of $7.9m starts to look very thin, hence the 'going concern' comments in the report. The answer? OPM.
RSH Price at posting:
8.9¢ Sentiment: Sell Disclosure: Not Held
